Interleukin-6 Receptor Soluble Fragment human

The receptor mediated activity of human IL-6 receptor soluble fragment is measured by its ability to increase the IL-6 inhibition of M1 cells.

Interleukin-6 Receptor soluble fragment elicits a 50% increase in IL-6 activity in cell based assay at a concentration (EC50) of 1-10 ng/ml.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Interleukin-6 is a pleotropic cytokine involved in hematopoiesis, inflammation and immune response. IL-6 is secreted by macrophages, dendritic cells and B cells, in response to TNF-α, PGDF and IL-1. The signaling by IL-6 is mediated by heterodimeric receptor, IL-6R, comprising of IL-6Rα (soluble factor) and gp130 (sometimes called IL-6Rβ). Gp130 is crucial component for downstream signal transduction. In response to IL-6, gp130 activates kinases of JAK family, STATs, MAPK and Ras proteins. IL-6R-mediated signaling is essential for normal development of T and B cells and has been implicated in many diseases such as rheumatoid arthritis, Crohn disease, sepsis, fever, systemic lupus erythematosus, osteoporosis and insulin resistance
Interleukin-6 Receptor soluble fragment specifically binds and inhibits the activity of human IL-6 in free form or when bound to cell surface receptors.

Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing 1.25 mg bovine serum albumin.